Pacifico
Trial overview
Phase 3
Older patients
Follicular Lymphoma
Comparison of 1st line R-CVP V R-FC
Inclusion criteria
|
Histologically confirmed follicular lymphoma (grade 1,2, and 3a with material available for central review) Ann Arbor stage II-IV Aged 60 years or over, or aged less than 60 but anthracycline-based therapy contra-indicated At least one of the following criteria for initiation of treatment: Rapid generalized disease progression in the preceding 3 months Life threatening organ involvement Renal or macroscopic liver infiltration Bone lesions Presence of systemic symptoms or pruritus Haemoglobin < 10 g/dL or WBC < 3.0 × 10 Adequate haematological function (unless abnormalities are related to lymphoma infiltration of the bone marrow): Haemoglobin ≥ 8.0 g/dL Absolute neutrophil count (ANC) ≥ 1.5 x 10 Platelet count ≥ 100 x 10 Written Informed Consent 9/L or platelet counts < 100 × 109/L due to marrow involvement 9/L 9/L |
Exclusion criteria
|
Prior anti-lymphoma treatment Overt transformation to diffuse large B-cell lymphoma Grade 3b follicular lymphoma Presence or history of CNS disease (either CNS lymphoma or lymphomatous meningitis) WHO performance status 3 or 4 Creatinine clearance < 30 mL/min Serum bilirubin more than twice upper limit of normal (unless due to lymphoma) Life expectancy less than 12 months Pre-existing neuropathy Active auto-immune haemolytic anaemia Serological evidence of infection with HIV, hepatitis B (positivity for surface antigen or core antibody) or hepatitis C Allergy to murine proteins Regular corticosteroid treatment during the last 4 weeks, unless administered at a dose equivalent to < 20 mg/day prednisolone Concomitant malignancies except non-melanoma skin cancer or adequately treated in situ cervical cancer Major surgery (excluding lymph node biopsy) within 28 days prior to randomisation Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease) Treatment within a clinical trial within 30 days prior to trial entry Any other co-existing medical or psychological condition that will preclude participation in the study or compromise ability to give informed consent Adult patient under tutelage (not competent to sign informed consent) Pregnant or lactating women All men or women of reproductive potential, unless using at least two contraceptive precautions, one of which must be a condom |
Contact details
Other trials currently active for Follicular Lymphoma
A Phase III multi-centre randomised controlled trial of low dose radiotherapy for follicular lymphoma.
Short CHemoRadioImmunotherapy in Follicular Lymphoma Trial of 90Y Ibritumomab tiuxetan (ZevalinTM) as therapy for first and second relapse in Follicular Lymphoma - a Prospective Phase II study